Item 8.01 Other Events.

As previously reported by HTG Molecular Diagnostics, Inc. (the "Company") in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on November 18, 2022, on November 18, 2022 the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") that, as a result of the Company's stockholders' equity falling below $2.5 million as reported in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company did not satisfy one of The Nasdaq Capital Market continued listing requirement set forth in Nasdaq Stock Market Rule 5550(b) (the "Rule").

On December 23, 2022, the Company completed a best-efforts public offering, pursuant to which the Company sold and issued to an institutional investor shares of its common stock, pre-funded warrants and other warrants for total gross proceeds of approximately $10.0 million. The estimated net proceeds of the offering are approximately $8.7 million, after deducting the placement agent fees and expenses and other estimated offering expenses payable by the Company. The offering and related matters are described in more detail in the Company's Current Report on Form 8-K filed with the SEC on December 23, 2022.

As of the date of this report, the Company believes it has regained compliance with the Rule based upon the net proceeds to the Company from the offering referenced above. Nasdaq will continue to monitor the Company's ongoing compliance with the Rule and, if at the time of the Company's next periodic report the Company does not evidence compliance with the Rule, the Company may be subject to delisting.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses